3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma | Haematologica
Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma | Research To Practice
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis - Clinical Lymphoma, Myeloma and Leukemia
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
ASCO 2019 Dr. Richardson on Isatuximab | Int Myeloma Fn
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
ICARIA-MM Study Updates| Int'l Myeloma Foundation
OPTIMISMM Trial - Slideset Download - Clin Onc June 2018 | CCO
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial - The Lancet Haematology
Trials
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies - Szabo - eJHaem - Wiley Online Library
Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse - ScienceDirect
Multiple Myeloma Support + Trials
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma - ScienceDirect
![PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/be4724496d6a2bc3c1ce363734069c2dc2a77f30/2-Figure1-1.png "PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar")
PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial - The Lancet Oncology
